Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Protocol No
HJKC3-0003
Phase
II
Summary

The purpose of this study is to determine if adding asciminib to imatinib prior to a second attempt at stopping imatinib will lead to prolonged treatment free remission.

Description
Treatment Free Remission After Asciminib plus Imatinib in CP-CML
Participating Institutions
Karmanos Cancer Institute
Memorial Sloan Kettering Cancer Center
University of Utah Huntsman Cancer Institute
Froedtert Hospital
Moorland Reserve Health Center
Memorial Sloan Kettering Cancer Center - Bergen
Lawrence And Idell Weisberg Cancer Treatment Center
Memorial Sloan Kettering Cancer Center - Monmouth
Status
OPEN TO ACCRUAL